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Abstract
The aim of the present study was to determine whether the endothelial dysfunction associated with CAD (coronary
artery disease) and T2D (Type 2 diabetes mellitus) is concomitant with elevated mtROS (mitochondrial reactive
oxygen species) production in the endothelium and establish if this, in turn, regulates the activity of endothelial
AMPK (AMP-activated protein kinase). We investigated endothelial function, mtROS production and AMPK activation
in saphenous veins from patients with advanced CAD. Endothelium-dependent vasodilation was impaired in patients
with CAD and T2D relative to those with CAD alone. Levels of mitochondrial H2O2 and activity of AMPK were
significantly elevated in primary HSVECs (human saphenous vein endothelial cells) from patients with CAD and T2D
compared with those from patients with CAD alone. Incubation with the mitochondria-targeted antioxidant, MitoQ10
significantly reduced AMPK activity in HSVECs from patients with CAD and T2D but not in cells from patients with
CAD alone. Elevated mtROS production in the endothelium of patients with CAD and T2D increases AMPK
activation, supporting a role for the kinase in defence against oxidative stress. Further investigation is required to
determine whether pharmacological activators of AMPK will prove beneficial in the attenuation of endothelial
dysfunction in patients with CAD and T2D.
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INTRODUCTION
The prevalence of CAD (coronary artery disease) in patients with
diabetes is notably higher than in the general population. Up to
a third of patients requiring coronary intervention have diabetes,
and outcome is poorer in these patients than in patients without
diabetes [1,2]. With the worldwide incidence and prevalence of
diabetes increasing, more individuals will be affected by CAD
and related complications and further pressure on health systems
is expected [3]. The relationship between diabetes and vascu-
lar disease is complex and multifactorial [1]. Increased vascular
Abbreviations: AICAR, 5-amino-4-imidazolecarboxamide riboside; AMPK, AMP-activated protein kinase; BMI, body mass index;CABG, coronary artery bypass graft; CAD, coronary artery
disease; CaMKK, Ca2 + /calmodulin-dependent kinase kinase; CVD, cardiovascular disease; 2DG, 2-deoxy-D-glucose; DTPP, decyl triphenylphosphonium bromide; eNOS, endothelial
nitric oxide synthase; GAPDH, encoding glyceraldehyde-3-phosphate dehydrogenase; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; HSVEC, human saphenous vein
endothelial cell; HUVEC, human umbilical vein endothelial cell; LDL, low-density lipoprotein; ROS, reactive oxygen species; mtROS, mitochondrial ROS; PRKAA1, encoding the AMPK-α1
catalytic subunit; SOD, superoxide dismutase; T2D, Type 2 diabetes; vWF, von Willebrand factor.
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oxidative stress has been proposed as a mechanism responsible
for impaired endothelial function in patients with diabetes [4],
but it is unknown whether these findings persist in the light of the
more aggressive primary and secondary prevention strategies to
which these vulnerable patients are subject [3].
Mitochondria are a major source of ROS (reactive oxygen
species) production in the vasculature and contribute to oxidative
stress and endothelial dysfunction in a range of cardiovascular
pathologies, including CAD and T2D (Type 2 diabetes mellitus)
[5,6]. However, mtROS (mitochondrial ROS) are also of im-
portance in cellular signalling and, at low O2 concentrations,
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mitochondria of HUVECs (human umbilical vein endothelial
cells) have been shown to generate ROS for activation of en-
zymes such as AMPK (AMP-activated protein kinase) [7].
Human AMPK is a heterotrimeric serine/threonine kinase,
consisting of a catalytic α-subunit and regulatory β- and γ -
subunits, each ofwhich has two ormore isoforms that are encoded
by distinct genes and differentially expressed in various tissues
[8]. Involved in the regulation of cellular and whole body energy
status [9], activation of AMPK requires phosphorylation at Thr172
by an AMPK kinase. Two AMPK kinases have been isolated
to date, LKB1 [10] and CaMKK (Ca2+ /calmodulin-dependent
kinase kinase) [11]. It has been proposed that LKB1 activity
is constitutive, such that stimuli which increase the AMP/ATP
ratio, including hypoxia, hypoglycaemia and ischaemia, inhibit
dephosphorylation at Thr172, permitting phosphorylation and ac-
tivation ofAMPKbyLKB1 [10]. In contrast, activation ofAMPK
by Ca2+ is AMP-independent and mediated by CaMKK [11,12].
More recently, AMPK activation via a ROS-mediatedmechanism
has been described [7,13–18].
Proposed as a candidate target for therapeutic intervention in
endothelial dysfunction, AMPK stimulates eNOS (endothelial
nitric oxide synthase), leading to NO production in cultured
endothelial cells [19]. Furthermore, stimulation of endothelial
AMPK is reported to attenuate pro-inflammatory signalling
[20,21] and there is accumulating evidence to suggest a role for
the kinase in defence against oxidative stress in the endothelium
[8,22,23].
The present study was designed to test the hypothesis that the
endothelial dysfunction associated with CAD and T2D occurs
in parallel with increased mtROS production in the endothelium
and that this, in turn, regulates endothelial AMPK activity.
MATERIALS AND METHODS
Detailed methods can be found in Supplementary Mater-
ials and methods section at http://www.clinsci.org/cs/124/
cs1240403add.htm.
Subjects
We recruited 79 volunteers with severe CAD from cardiothoracic
pre-operative clinics. A blood sample was taken after 3 h of fast-
ing on the day of admission for CABG (coronary artery bypass
graft) surgery. Twenty three volunteers had a history of T2D. T2D
was defined as having fasting venous blood glucose6.1 mmol/l
or 10 mmol/l 2 h post-oral glucose load (75 g). We also re-
cruited 19 control volunteers free of evidence of CAD who were
undergoing surgery for the removal of varicose veins. For these
volunteers, a blood sample was taken following 3 h of fasting 1–2
weeks after surgery. The study complies with the Declaration of
Helsinki and was approved by the local ethics committee. All
participants gave written informed consent.
Preparation of vascular tissue
Surplus portions of freshly harvested saphenous veins from vo-
lunteers undergoing CABG surgery or elective varicose vein re-
moval were stored in sterile saline solution. Maximum storage
time was 2 h. Only non-varicosed portions of veins from con-
trol patients, as identified by the surgical team, were utilized.
Samples were taken to the laboratory and cleaned of excess con-
nective tissue. Endothelial cells were isolated from sections of
samples on the day of surgery and the remainder of samples stored
at 4 ◦C in a Krebs Hepes buffer (118 mmol/l NaCl, 10 mmol/l
Hepes/NaOH, pH 7.4, 25 mmol/l NaHCO3, 4.7 mmol/l KCl,
1.2 mmol/l MgSO4, 1.2 mmol/l KH2PO4, 11 mmol/l glucose,
10 μmol/l indomethacin and 50 μmol/l EDTA) for study of en-
dothelial function the following day.
Assessment of endothelial function
Rings (3 mm) of saphenous veinwere studied in organ bath cham-
bers as previously described [24]. Vessels were constricted with
phenylephrine (3 μmol/l) and relaxation in response to the cal-
cium ionophore A23187 (0.01–10 μmol/l) was studied. Max-
imum relaxation was calculated and is expressed as a percentage
of constriction in response to phenylephrine.
Cell culture
HSVECs (human saphenous vein endothelial cells) were isol-
ated on the day of surgery by standard collagenase digestion
based on a modified version of the protocol described by Jaffe
et al. [25]. Cells were cultured in complete Large Vessel En-
dothelial Cell Basal Medium (TCS Cellworks), supplemented
with 20% (v/v) FBS (fetal bovine serum), 100 units/ml peni-
cillin, 100 μg/ml streptomycin and 2 mmol/l L-glutamine. Cells
were used at passage 3 and all experimental procedures were
carried out when cells were about 80% confluent.
For immunofluorescent staining of vWF (von Willebrand
factor), passage 3HSVECswere harvested and plated onto sterile
coverslips before being fixed in 4% (w/v) PFA (paraformalde-
hyde). Cells were then incubated with mouse anti-vWF primary
antibody [1:50 dilution in 20% (v/v) goat serum/PBS] followed
by goat-anti-(mouse IgG)–FITC-conjugated secondary antibody
(1:200 dlution in 20% (v/v) goat serum/PBS; Dako). Coverslips
were subsequently mounted in Vectashield (Vector Laborator-
ies), containing propidium iodide for nucleic counter-staining,
and cells visualized under a fluorescence microscope (Olympus
BX40).
Assessment of mitochondrial H2O2 production
Measurement of HSVEC mitochondrial H2O2 production was
carried out using the mitochondria-targeted H2O2 MS probe,
MitoB, as described previously for cell culture experiments [26].
Where required, HSVECs were incubated at 37 ◦C in medium
supplemented with 1 μmol/l MitoQ10 for 1 h prior to washing
in PBS and incubation in medium supplemented with 5 μmol/l
MitoB for 6 h.
mRNA expression
Total RNA was extracted from HSVECs using the RNeasy®
Mini Kit (QIAGEN) and quantified (NanoDrop ND-100 Spec-
trophotometer). cDNA was synthesized from 1 μg of DNase-
treated (TURBO DNA-freeTM; Ambion) total RNA (TaqMan®
Reverse Transcription Reagents; Applied Biosystems). Relative
quantification ofPRKAA1 (encoding theAMPK-α1 catalytic sub-
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Table 1 Characteristics of the study cohort
Continuous data are given as means +− S.D., irrespective of distribution or skewness. P values, however, derive from a
Student’s t test or Mann–Whitney U test as appropriate. Comparison between categorical data was performed using Fisher’s
exact test. SBP, systolic blood pressure; DBP, diastolic blood pressure; TAG, triacylglycerol; CRP, C-reactive protein; HbA1c,
glycosylated haemoglobin; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type I receptor blocker. ∗With
T2D compared with Without T2D; †CAD compared with controls.
CAD patients
Parameter With T2D (n=23) Without T2D (n=56) P value∗ Controls (n=19) P value†
Age (years) 65 +− 11 65 +− 9 0.961 44 +− 19 <0.001
Sex (male/female) (n) 20/3 45/11 0.747 8/11 0.001
BMI (kg/m2) 31.7 +− 5.2 28.6 +− 4.7 0.026 26.5 +− 1.9 0.004
SBP (mmHg) 138 +− 22 138 +− 26 0.897 132 +− 23 0.471
DBP (mmHg) 73 +− 13 80 +− 11 0.065 84 +− 12 0.162
Total cholesterol (mmol/l) 3.95 +− 1.10 4.11 +− 0.99 0.542 4.96 +− 0.99 0.029
LDL-cholesterol (mmol/l) 1.80 +− 0.83 2.00 +− 0.78 0.314 2.69 +− 1.11 0.024
HDL-cholesterol (mmol/l) 1.11 +− 0.22 1.17 +− 0.27 0.366 1.72 +− 0.30 <0.001
TAG (mmol/l) 2.54 +− 1.97 2.04 +− 0.97 0.262 1.17 +− 0.47 0.052
CRP (mg/l) 2.5 +− 2.9 5.0 +− 10.5 0.280 3.5 +− 4.2 0.843
HbA1c (%) 7.2 +− 1.3 5.6 +− 0.4 <0.001 5.4 +− 0.2 0.111
Active smoking (yes/no) (n) 2/22 2/54 0.579 2/17 0.324
ACEI/ARB (yes/no) (n) 18/5 32/24 0.122 1/18 <0.001
Statin (yes/no) (n) 21/2 53/3 0.625 2/17 <0.001
Metformin (yes/no) (n) 10/13 0/56 <0.001 0/19 <0.001
unit) expression, relative to GAPDH (encoding glyceraldehyde-
3-phosphate dehydrogenase), was calculated using the compar-
ative (Ct) method [27].
AMPK activity assay
HSVECs were serum-starved overnight before being in-
cubated for 1 h at 37 ◦C in Krebs Ringer Hepes buffer
(119 mmol/l NaCl, 20 mmol/l Hepes, pH 7.4, 5 mmol/l NaHCO3,
4.7 mmol/l KCl, 1.3 mmol/l CaCl2, 1.2 mmol/lMgSO4, 1 mmol/l
KH2PO4, 0.1 mmol/l L-arginine, 5 mmol/l glucose) in the pres-
ence of 1 μmol/l MitoQ10, 1 μmol/l DTPP (decyl triphen-
ylphosphonium bromide) and 2 mmol/l AICAR (5-amino-4-
imidazolecarboxamide riboside) where required. Cell lysates
were prepared andAMPK immunoprecipitated and assayed using
the SAMS peptide as previously described [28].
Statistical analyses
For clinical data and measurements in whole vessels, continuous
data are given as means+−S.D. or medians (interquartile range)
unless otherwise indicated. Values stated are means+− S.E.M. for
cellular data. For comparisons of a continuous variable between
two experimental groups, paired and unpaired Student’s t test
and Mann–Whitney U tests were applied as appropriate. For
comparisons of a continuous variable in datasets with more than
two groups, ANOVA was applied, followed by the Tukey’s post-
hoc test for all possible pairwise comparisons. Categorical data
were analysed by Fisher’s exact test. A P value of less than 0.05
(two-tailed) was considered significant.
RESULTS
Characteristics of study participants
Demographic and clinical characteristics of patients and control
subjects are given in Table 1. As expected, patients with CAD
were older and more likely to be on cardiovascular medication
than control subjects. Total cholesterol and LDL (low-density
lipoprotein)-cholesterol levels were lower in patients with CAD
compared with control subjects, consistent with lipid-lowering
therapy in the patient group. HDL (high-density lipoprotein)-
cholesterol levels were significantly greater in control subjects
compared with patients. Patients with T2D had a greater BMI
(body mass index) and a greater percentage of HbA1c (glycated
haemoglobin), but no other significant differences to patients
without diabetes were observed. A total of ten out of the 23
patients with T2D (43%) were treated with metformin.
Endothelial function
Endothelium-dependent relaxation was impaired in vessels of
patients with CAD compared with those obtained from control
subjects (maximum relaxation in response to A23187, 43+− 16
compared with 62+− 16%; P= 0.001; Figures 1A and 1C). Pa-
tients with CAD and T2D had significantly reduced endothelium-
dependent relaxation comparedwith thosewithCADalone (max-
imum relaxation in response to A23187, 34+− 11 compared with
47+− 16%; P= 0.008; Figures 1B and 1C). See Supplementary
Figure S1 (at http://www.clinsci.org/cs/124/cs1240403add.htm)
for data in saphenous veins concerning the vasorelaxation
in response to carbachol and Supplementary Figures S1
and S2 (at http://www.clinsci.org/cs/124/cs1240403add.htm) for
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Figure 1 Vasorelaxation in human saphenous veins
Maximum relaxation of saphenous vein in response to the endothelium-dependent vasodilator calcium ionophore A23187
(A, B). (A) Comparisons between patients with CAD (n= 49) and control subjects (n= 10). (B) Comparisons between
patients with CAD and T2D (n= 14) and patients with CAD alone (CAD ND, n= 35). (C) Dose–response curves to A23187
for the three groups (means +− S.E.M.).
endothelium-dependence of the relaxation in response to car-
bachol and A23187.
Mitochondrial H2O2 production in primary HSVECs
It has been demonstrated that mtROS contribute to the oxidative
stress and endothelial dysfunction characteristic of CVD (car-
diovascular disease) [5,6]. To establish whether increased levels
of mitochondrially produced H2O2 were concomitant with the
endothelial dysfunction observed in vessels from patients with
CAD, we investigated mitochondrial H2O2 production in primary
HSVECs (Figure 2A) isolated from these patients and control
subjects.
Significantly greater mitochondrial H2O2 production was
noted in HSVECs from CAD patients with T2D relative to those
frompatientswithCADalone (MitoP/MitoB ratio, 0.054+− 0.003
compared with 0.042+− 0.003; P= 0.02; Figure 2B). This find-
ing was independent of mitochondria number (Supplementary
Figure S3 at http://www.clinsci.org/cs/124/cs1240403add.htm).
The mitochondrial-targeted antioxidant MitoQ10 had no signific-
ant effect on basal mitochondrial H2O2 production in HSVECs
frompatientswithCADalone (MitoP/MitoB ratio, 0.042+− 0.003
comparedwith 0.044+− 0.004;P= 0.61; Figure 2B), patientswith
CADandT2D (MitoP/MitoB ratio, 0.054+− 0.003 comparedwith
0.052+− 0.004; P= 0.35; Figure 2B) and control subjects (Mi-
toP/MitoB ratio, 0.043+− 0.006 compared with 0.045+− 0.003,
P= 0.58; Figure 2B).
AMPK activation in primary HSVECs
AMPK has recently been implicated in attenuation of endothelial
oxidative stress [8,22,23]. In addition, the kinase has been shown
to be activated in response to a variety of ROS, including H2O2
[13,18,29].
As shown in Figure 3(A), activity of AMPK was increased
in cells from CAD patients as compared with those from
control subjects (0.045+− 0.007 compared with 0.022+− 0.006
nmol ·min− 1 ·mg− 1; P= 0.05). When compared with control
subjects, a greater increase in AMPK activity was observed
in HSVECs from patients with CAD and T2D (0.062+− 0.011
compared with 0.022+− 0.006 nmol ·min− 1 ·mg− 1; P= 0.01;
Figure 3A) than in cells from patients with CAD alone
(0.031+− 0.005 compared with 0.022+− 0.006 nmol ·min− 1 ·
mg− 1; P= 0.26; Figure 3A). AMPK activity was significantly
higher in HSVECs from patients with CAD and T2D than in
those from patients with CAD alone (0.062+− 0.011 compared
with 0.031+− 0.005; P= 0.01; Figure 3A).
No change in the mRNA expression of PRKAA1, encod-
ing the AMPK-α1 catalytic subunit, was observed between
patient groups (Figure 3B), consistent with modulation of
AMPK activity via post-translational modification. In ad-
dition, there was no significant difference in protein ex-
pression of AMPK-α1 (Supplementary Figure S4 at http://
www.clinsci.org/cs/124/cs1240403add.htm) or the upstream
AMPK kinase LKB1 (Supplementary Figure S5 at http://
www.clinsci.org/cs/124/cs1240403add.htm), as assessed by im-
munoblotting.
AMPK substrate phosphorylation in primary
HSVECs
Given the increased AMPK activity observed in HSVECs from
patients with CAD and the poorer endothelial function of these
subjects, phosphorylation of eNOS, an AMPK substrate, was in-
vestigated in cells from these CAD patients by means of immun-
oblotting (Figure 4A). Densitometric analysis revealed signific-
antly lower basal eNOS phosphorylation in HSVECs from CAD
patients with T2D (Figure 4B), despite the increased basal AMPK
activity in these cells (Figure 3A). Incubation of HSVECs with
AICAR, an artificial activator ofAMPK [30], appeared to result in
increased eNOS phosphorylation in cells from patients with CAD
alone, although results were not significant (Figure 4B). However,
AICAR treatment failed to stimulate eNOS phosphorylation in
HSVECs from those CAD patients with T2D (Figure 4B).
Mitochondrial ROS-mediated AMPK activation
in primary HSVECs
Vascular endothelial cells have been reported to be highly glyco-
lytic [7]. In support of this, HSVEC ATP synthesis was largely
the result of glycolysis, as assessed by the relative effects of 2DG
(2-deoxy-D-glucose) and rotenone (Supplementary Figure S6 at
http://www.clinsci.org/cs/124/cs1240403add.htm).
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Figure 2 Mitochondrial H2O2 production in HSVECs
(A) Representative photomicrographs showing HSVECs in primary culture. Endothelial cells were successfully isolated, as
determined by their characteristic cobblestone morphology (left-hand panel) and positive staining (green) for vWF (middle
and right-hand panels). (B) HSVEC mitochondrial H2O2 production was determined using the mitochondria-targeted MS
probe, MitoB, in both the presence and absence of the mitochondria-targeted antioxidant, MitoQ10. ∗P< 0.05 compared
with CAD ND. CAD ND, CAD patients without T2D (n= 4); CAD T2D, CAD patients with T2D (n= 4); controls, control
subjects (n= 3).
An alternative, potentially significant role for endothelial mi-
tochondria is the generation of ROS for signalling purposes [7].
The contribution of mtROS to AMPK activation was investigated
by treating HSVECs from CAD patients with MitoQ10 and sub-
sequently assaying AMPK activity. To control for non-specific
effects of MitoQ10, cells were treated with the non-active control
compound, DTPP [31]. Exposing HSVECs to MitoQ10 resul-
ted in a reduction in AMPK activity (Figure 5). The MitoQ10-
mediated decrease in AMPK activity was greater in HSVECs
from CAD patients with T2D (0.056+− 0.004 compared with
0.009+− 0.01 nmol ·min− 1 ·mg− 1; P= 0.02; Figure 5B) than in
those from patients with CAD alone (0.035+− 0.005 compared
with 0.014+− 0.0002 nmol ·min− 1 ·mg− 1; P= 0.06; Figure 5A).
Treating HSVECs from CAD patients with AICAR resulted
in a significant increase in kinase activity in cells from patients
with CAD alone (0.035+− 0.005 compared with 0.095+− 0.01
nmol ·min− 1 ·mg− 1; P= 0.05; Figure 5A).
DISCUSSION
Increased vascular oxidative stress has been proposed as one
potential mechanism underlying endothelial dysfunction in pa-
tients with CAD and T2D [4]. The present study involved in-
vestigation of endothelial function and molecular determinants
of oxidative stress in human saphenous veins. Previous studies
have demonstrated human arterial and venous levels of oxidat-
ive stress are closely related [32,33], such that results should
not be affected by the choice of vessel. Herein we report im-
paired endothelium-dependent relaxation in vessels from patients
with advanced CAD. Poorer endothelial function was observed
in those CAD patients with the additional cardiovascular risk
factor, T2D. To investigate the molecular basis for the impaired
endothelium-dependent relaxation in vessels from patients with
CAD and T2D, endothelial cells were isolated from vascular tis-
sue. Endothelial dysfunction was observed to be maintained in
culturewith significantly lower levels of basal eNOSSer1177 phos-
phorylation in cells from CAD patients with T2D as compared
with those with CAD alone. As isolated cells were maintained in
culture for several weeks prior to investigation, it seemed likely
that the effects of pharmacological treatments (including met-
formin, a known activator of AMPK [8]) would be lost, allowing
more accurate insight into molecular determinants of impaired
endothelial function and potentially causative oxidative stress.
The mitochondrial electron transport chain has been identi-
fied as a major source of ROS in the vasculature, contributing
to the oxidative stress and endothelial dysfunction character-
istic of CAD and T2D [5,6]. As such, following isolation and
characterization of HSVECs, we investigated cellular mitochon-
drial H2O2 production and observed an increase in cells from
patients with CAD and T2D which was not due to an increase in
mitochondria number. Known to induce endothelial dysfunction
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Figure 3 AMPK activation in HSVECs
(A) Total AMPK activity in immunoprecipitates from HSVEC lysates cul-
tured at 21 % O2. †P< 0.01 compared with control subjects, ‡P< 0.01
compared with CAD ND. (B) HSVEC PRKAA1 mRNA expression relative
to GAPDH. RQ, relative quantification; CAD ND, CAD patients without
T2D; CAD T2D, CAD patients with T2D.
[34], increased levels of mitochondrially produced H2O2 may
therefore have a causal role in the significantly impaired vasore-
laxation of CAD patients with T2D.
Vascular endothelial cells are recognized as being highly gly-
colytic and we have confirmed this to be the case for HSVECs.
A potential reason for the favouring of glycolysis by endothelial
cells has been proposed by Quintero and co-workers [7], whereby
mitochondria are not preferentially used bioenergetically in these
cells, allowing them to function primarily in the generation of
ROS for signalling purposes, resulting in activation of enzymes,
including AMPK.
Traditionally associated with maintenance of cellular energy
homoeostasis, it is well documented that AMPK is activated
in response to the increased AMP/ATP ratio characteristic of
hypoxic stress. With regard to endothelial AMPK specifically,
phosphorylation of the kinase has been observed at low O2 con-
centrations in HUVECs but is undetectable at 21% O2 or ‘nor-
moxia’ [7]. However, it has been suggested that kinase activation
at low O2 concentrations may occur via a mechanism that is
independent of altered nucleotide levels but is mtROS-mediated
[7,13]. Interestingly, we were able to assay AMPK activity in HS-
VECs isolated from patients with CAD and cultured under nor-
moxic conditions, indicating CVD phenotype could be linked to
enzyme activation. Indeed, at 21% O2, HSVEC AMPK activity
was significantly greater in cells from patients with CAD relative
to control subjects. On stratifying CAD patients according to the
presence of T2D, we found AMPK activity to be significantly
increased in the endothelium of patients with CAD and T2D as
Figure 4 Comparison of eNOS Ser1177 phosphorylation in HSVECs
HSVECs were isolated from CAD patients with (CAD T2D, n= 5) and
without (CAD ND, n= 5) T2D and eNOS Ser1177 phosphorylation in
the presence or absence of AICAR assessed by Western blotting of
cell lysates. (A) Representative immunoblots from two CAD patients
with and two CAD patients without T2D. (B) Densitometric analysis of
the P-eNOS (phospho-eNOS Ser1177)/eNOS ratio relative to an internal
standard lysate.∗P< 0.05 compared with CAD T2D (vehicle).
comparedwith that of patientswithCADalone, despite no change
in AMPKα1 expression or difference in levels of the upstream
AMPK kinase LKB1. Incubating HSVECs with AICAR, an arti-
ficial, ROS-independent activator of AMPK, known to stimulate
the kinase in endothelial cells [19], resulted in a significant in-
crease in AMPK activity in cells from patients with CAD alone
but not in cells from those patients with CAD and T2D whose
basal AMPK activity approached maximal levels.
Given the elevated mitochondrial H2O2 production in HS-
VECs from patients with CAD and T2D, in addition to the glyco-
lytic nature of the cells, it seemed likely that enhanced endothelial
AMPK activation was occurring in an mtROS-mediated manner
in these patients. In order to test this hypothesis, we treated HS-
VECs isolated fromCADpatientswith themitochondria-targeted
antioxidant, MitoQ10, which has been shown to prevent oxidative
damage in endothelial cells in vitro [35]. Our findings demon-
strated a significant decrease in AMPK activation on treatment
with MitoQ10 in cells from those patients with T2D. The non-
antioxidant control for MitoQ10, DTPP, had no effect on AMPK
activity in a parallel experiment, indicating results can be attrib-
uted to the antioxidant action of MitoQ10 specifically. The same
effect was not seen in cells from CAD patients without T2D.
Taken together, our findings indicate a novel, mtROS-
mediated activation of AMPK in the endothelium of patients
withCADandT2D. In terms ofmtROS likely to be involved in ac-
tivation of the kinase, in concordance with results presented here,
a role for H2O2 has been reported [13,18,29]. However, MitoQ10
does not act by directly lowering H2O2 production [36], con-
firmed via investigation of HSVEC mitochondrial H2O2 levels
in the presence and absence of the antioxidant. Therefore the
signal emanating frommitochondria and activating AMPK in the
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Figure 5 Effect of mitochondrial-ROS on AMPK activation in
HSVECs
(A) Cells from CAD patients without T2D (CAD ND, n= 5) and (B) with
T2D (CAD T2D, n= 5) were incubated in the presence ( + ) of MitoQ10,
DTPP and AICAR. Total AMPK was immunoprecipitated from lysates
which were then assayed for AMPK activity.∗P= 0.05 compared with
basal value for CAD ND; †P< 0.05 compared with basal value for CAD
T2D; ‡P< 0.01 compared with + DTPP value for CAD T2D.
endothelium of patients with CAD and T2D is unlikely to
be H2O2 itself, but rather a downstream radical with which
MitoQ10 reacts. Such radicals include lipid peroxidation
products, generated on oxidation of mitochondrial lipids by
H2O2.
Recent studies suggest AMPK activation improves en-
dothelial function by counteracting oxidative stress in the en-
dothelium. Indeed, the kinase suppresses NADPH oxidase and
ROS production in endothelial cells [23] and stimulates NO pro-
duction by eNOS, inducing endothelium-dependent vasodilation
[37]. In addition, AMPK activation attenuates pro-inflammatory
signalling and monocyte adhesion to the endothelium [20]. Fur-
thermore, metformin, known to exert a portion of its effect
through AMPK, has been reported to decrease intracellular pro-
duction ofmtROS in aortic endothelial cells [38], while activation
of AMPK has been observed to reduce hyperglycaemia-induced
mtROS production by induction of the endogenous mitochon-
drial antioxidant, SOD2 (superoxide dismutase 2) in HUVECs
[39]. Similarly, Colombo and Moncada [22] have demonstrated
that endothelial AMPKα1 is responsible for the expression of
a number of genes involved in antioxidant defence, including
SOD2.
Our observations that eNOS Ser1177 phosphorylation is sig-
nificantly reduced in cells from CAD patients with T2D im-
plies that elevated AMPK activity alone against a background
of T2D is not sufficient to increase eNOS phosphorylation
at this residue. It could perhaps be the case that a phos-
phatase is activated in these patients or that this additional
CVD risk factor results in eNOS being regulated in an al-
ternative manner, rendering it much more difficult to phos-
phorylate. Interestingly, AMPK has recently been shown to phos-
phorylate eNOS at the additional residue Ser633 and ablation
Figure 6 Proposed mechanism of mtROS-mediated AMPK activation in endothelial cells
The results suggest a potentially mtROS-mediated increase in AMPK activity in patients with CAD and T2D. The mtROS
in question are likely to be downstream derivates of H2O2, such as lipid peroxidation products. AMPK may therefore be
part of a feedback or adaptive mechanism with a role in defence against oxidative stress in the endothelium, attenuating
pro-inflammatory signalling and regulating expression of antioxidant genes, including SOD2. However, increased kinase
activity does not appear to be sufficient to stimulate activation of eNOS, in patients with T2D.
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of AMPKα2 was observed to be sufficient to inhibit
atorvasatin-stimulated eNOSphosphorylation at both this residue
and Ser1177, despite AMPKα1 being the principle isoform in
terms of total cellular activity [40]. Consequently, it is feasible
that the increased AMPK activity observed in CAD patients
with T2D reflects increased AMPKα1 activity alone and that
AMPKα2 activity is required for eNOS Ser1177 phosphorylation.
In accordance with our findings, Wang et al. [41] have reported
that HUVECs subject to low glucose concentrations demonstrate
reduced NO bioavailability associated with increased mtROS
production andAMPK activation, yet this fails to stimulate eNOS
phosphorylation.
In the endothelium of patients with CAD and T2D, AMPK
may be part of a feedback or adaptive mechanism, wherein el-
evated mtROS production results in activation of AMPK which,
in turn, stimulates protective responses which may contribute to-
wards, but are not solely responsible for, increasing NO bioavail-
ability and attenuating endothelial dysfunction. Although not in-
vestigated here, the mtROS-activated AMPK may also induce
SOD2 activity, thus counteracting mitochondrial oxidative stress
and generating H2O2 for further kinase activation and perpetu-
ation of the cycle (Figure 6).
In summary, our results demonstrate elevated mtROS produc-
tion in the endotheliumof patientswithCADandT2D, suggesting
mitochondria contribute to the more severe endothelial dysfunc-
tion observed in these patients. In addition, we have shown a
novel, mtROS-mediated mechanism for AMPK activation in the
endothelium of patients with CAD and T2D. Although this novel
AMPK activation supports a role for the kinase in counteraction
of oxidative stress, we demonstrate that increased AMPK activity
does not simply translate to increased eNOS phosphorylation in
these subjects and is therefore not sufficient to attenuate the more
severe endothelial dysfunction characteristic of diabetic patients.
CLINICAL PERSPECTIVES
 Increasing evidence exists to suggest that elevated mtROS
production may contribute to poorer endothelial function in
patients with CAD and T2D compared with patients without
T2D.
 In the present study, we have demonstrated significantly in-
creased levels of mtROS in primary endothelial cells from
patients with CAD and T2D and a concomitant increase in
endothelial AMPK activity. This enhanced kinase activity is,
however, insufficient to increase eNOS phosphorylation.
 Further investigation is required to determine whether phar-
macological activators of AMPK will prove benefical in at-
tenuating endothelial dysfunction in patients with CAD and
T2D.
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MATERIALS AND METHODS
Reagents
Endothelial cell culture medium was obtained from TCS Cell-
works (Botolph Claydon) and PromoCell. The mouse anti-
vWF antibody was obtained from Dako. Rabbit anti-phospho-
AMPK-α1-Thr172 and anti-LKB1 antibodies were from Cell
Signaling Technology, and sheep anti-AMPK-α1 antibody was
generously provided by Professor D.G. Hardie (University of
Dundee, Dundee, U.K.). 2DG and rotenone were purchased
Figure S1 Vasodilation in response to carbachol and A23187 in saphenous vein samples from patients with CAD but
without T2D
Experiments were performed in saphenous vein samples from three patients with CAD but without T2D. Vasodilation
was induced by carbachol (left-hand panel) or calcium ionophore A23187 (right-hand panel). There were no significant
differences in the maximum relaxation in response to either compound (filled symbols; 80 % compared with 58 %), but
significant blunting of the response after pre-incubation (30 min) with L-NAME (NG-nitro-L-arginine methyl ester; 0.1 mmol/l;
open symbols) in both sets of experiments.
Correspondence: Dr Christian Delles (email Christian.Delles@glasgow.ac.uk).
from Sigma. Custom TaqMan® Gene Expression Assays for
PRKAA1 (Hs01562315_m1),MT-CYB (mitochondrially encoded
cytochrome b; Hs02596867_s1) and HBB (β-haemoglobin;
Hs00758889_s1), and TaqMan® Endogenous Control GAPDH
(4326317E) were from Applied Biosystems. AICAR was pur-
chased from Toronto Research Chemicals and MitoB, MitoQ10
mesylate and DTPP were from Professor Robin Smith (Depart-
ment of Chemistry, University of Otago, Dunedin, NewZealand).
The SAMS peptide (HMRSAMSGLHLVKRR) was synthesized
by Pepceuticals.
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Figure S2 Relaxation in response to the calcium ionophore
A23187 in endothelium-denuded rings of saphenous vein from
patients (n = 3) with CAD but without T2D
Response to A23187 is significantly blunted compared with experi-
ments in endothelium-intact vessels (see Supplementary Figure S1).
Means+−S.E.M. are displayed.
Figure S3 Determination of mitochondrial number in HSVECs by
PCR
Total DNA was isolated from HSVECs using the QIAamp® DNA Mini
Kit (Qiagen) and 25 ng used for PCR reactions. Using TaqMan® Gene
Expression Assays (Applied Biosystems) for single copy nuclear HBB
and MT-CYB, abundance of mitochondrial DNA relative to nuclear DNA
was determined by calculating Ct (cycle threshold value) ratios for each
patient. No difference in Ct ratio between patient groups was observed,
indicating HSVEC mitochondrial numbers do not vary across the groups.
CAD ND, CAD patients without T2D; CAD T2D, CAD patients with T2D.
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Figure S4 AMPKα1 expression in HSVECs
Cells were incubated in the presence ( + ) or absence ( − ) of AICAR (2 mmol/l), an artificial ROS-independent activator of
AMPK known to stimulate the kinase in intact cells [1]. Lysates were then prepared from HSVECs of control subjects (n =
5), and CAD patients without T2D (CAD ND, n = 5) and with T2D (CAD T2D, n = 5) in the same way as described previously
[2]. Lysates were subjected to Western blotting and probed with sheep anti-AMPK-α1 antibody (1:1000 dilution) before
incubation with donkey anti-rabbit IgG (1:1000 dilution; GE Healthcare). Resultant immunoblots demonstrated no change
in AMPK-α1 expression between patient groups under basal conditions or conditions stimulating AMPK phosphorylation.
Figure S5 LKB1 expression in HSVECs
Cells were incubated in the presence ( + ) or absence ( − ) of AICAR (2 mmol/l)) and lysates prepared from HSVECs of
control subjects (n = 5), and CAD patients without T2D (CAD ND, n = 5) and with T2D (CAD T2D, n = 5) in the same
way as described previously [2]. Lysates were subjected to Western blotting and probed with sheep anti-LKB1 antibody
(1:500 dilution) before incubation with protein G-peroxidase from Streptococcus sp. (1:1000 dilution; Sigma). Resultant
immunoblots demonstrate no change in LKB1 activity between patient groups under basal conditions or conditions
stimulating AMPK phosphorylation.
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Figure S6 ATP production in HSVECs
Determination of the contribution of oxidative phosphorylation and gly-
colysis to the generation of ATP in HSVECs was carried out in Professor
Moncada’s laboratory, using the method described by Quintero and co–
workers [3]. HSVECs isolated from CAD patients were grown for 24 h
in 96-well plates (PerkinElmer 3603 clear bottom, black walls, seeding
density 10000 cells per well) in phenol-red free ECM2 supplemented
with 2 % (v/v) FBS. On the day of the experiment, fresh medium was ad-
ded and cells pretreated with 20 mmol/l 2DG and 0.5 μmol/l rotenone
(both Sigma). 2DG is a glycolytic pathway inhibitor and rotenone, an
inhibitor of the mitochondrial respiratory chain [3]. ATP was measured
by the luciferin/luciferase method with the PerkinElmer ATPliteTM Lumin-
escence Assay System, following the manufacturer’s protocol. Chemi-
luminescence was determined in a TopCount (Packard Biosciences).
The addition of 2DG causes a greater decrease in intracellular ATP pro-
duction than the addition of rotenone and there is an additive effect
when inhibitors are used in combination. Results support findings that
endothelial cells are highly glycolytic [3]. *and †P< 0.0001 relative to
basal values for untreated cells.
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